Peripheral Nervous System Neoplasms: Clinical Trials

135 trials for Peripheral Nervous System Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 completed, 21 terminated, 18 recruiting, 12 active not recruiting. 135 Phase 2, 29 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2135Completed 65, Terminated 21, Recruiting 18, Active not recruiting 12, Unknown 8, Not yet recruiting 6, Withdrawn 4, Enrolling by invitation 1
Phase 129Completed 8, Recruiting 7, Terminated 6, Active not recruiting 4, Not yet recruiting 2, Enrolling by invitation 1, Unknown 1
Phase 33Terminated 2, Completed 1

Follow Peripheral Nervous System Neoplasms: new trials by email Literature Review of Peripheral Nervous System Neoplasms trials Research Report on Peripheral Nervous System Neoplasms

Trials (filtered) newest first · largest first

All 135 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)
Phase 2Not yet recruitingGirish Dhall, MD252027-01-012026-10-28
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1
Phase 2RecruitingUniversity of Alabama at Birmingham412026-08-042026-08-24
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST
Phase 1 / Phase 2RecruitingAnkit Mangla, MD172026-08-012026-08-11
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2Not yet recruitingBeijing Tiantan Hospital2002026-07-182026-07-20
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Florida272026-02-112026-06-30
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 2RecruitingUniversity of Alabama at Birmingham2002025-08-272026-05-29
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1 / Phase 2Not yet recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.652025-06-122025-06-17
Using CICS-1 and SPM-011 and [18F]FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
BNCT, [18F]FBPA - Thoracic Solid Malignant Tumor
Phase 1 / Phase 2Enrolling by invitationStella Pharma Corporation302025-04-102025-11-19
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma
Phase 2RecruitingFudan University452025-02-252026-01-08
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
HLX-1502 - Neurofibromatosis Type 1
Phase 2RecruitingHealx Limited252025-02-102026-07-29
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingEli Lilly and Company272025-01-172026-11-04
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
Selumetinib - Plexiform Neurofibromas (PN)
Phase 2Not yet recruitingWest China Hospital502025-01-012025-01-08
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2CompletedReveal Pharmaceuticals Inc.182024-08-152025-12-26
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
FCN-159 - Nerve Sheath Tumor
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences302024-08-152025-07-29
Agnostic Therapy in Rare Solid Tumors
Nivolumab - Urachal Cancer, Parathyroid Carcinoma
Phase 2Active not recruitingInstituto do Cancer do Estado de São Paulo282024-07-162026-10-13
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital1392024-03-272026-08-03
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma
Phase 2RecruitingHRYZ Biotech Co.1482024-02-212025-07-24

Showing 20 of 135. Sign in to see all of them.

Narrower conditions

Neurofibrosarcoma (57)  ·  Sarcoma (45)  ·  Neurofibromatosis 1 (33)  ·  Leiomyosarcoma (30)  ·  Sarcoma, Synovial (29)  ·  Neurofibroma, Plexiform (28)  ·  Histiocytoma, Malignant Fibrous (25)  ·  Liposarcoma (24)  ·  Fibrosarcoma (23)  ·  Neuroma, Acoustic (22)  ·  Hemangiosarcoma (21)  ·  Optic Nerve Glioma (21)  ·  Rhabdomyosarcoma (20)  ·  Astrocytoma (19)  ·  Sarcoma, Alveolar Soft Part (17)

Broader conditions

Neoplasms by Histologic Type (135)  ·  Nervous System Diseases (135)  ·  Nervous System Neoplasms (135)  ·  Neoplasms, Nerve Tissue (134)  ·  Neoplasms (133)  ·  Nerve Sheath Neoplasms (110)  ·  Neurofibroma (99)  ·  Neuromuscular Diseases (98)  ·  Peripheral Nervous System Diseases (96)  ·  Neoplasms, Connective and Soft Tissue (64)  ·  Neoplasms by Site (62)  ·  Neoplasms, Connective Tissue (62)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (59)  ·  Neuroectodermal Tumors (59)

Interventions

AZD 6244 (13)  ·  Doxorubicin (10)  ·  Imatinib Mesylate (6)  ·  Bevacizumab (5)  ·  Carboplatin (5)  ·  Everolimus (5)  ·  Ifosfamide (5)  ·  Radiotherapy (5)  ·  Temozolomide (5)  ·  pazopanib (5)  ·  Sirolimus (4)  ·  Etoposide (3)  ·  Vincristine (3)  ·  pembrolizumab (3)  ·  trametinib (3)

Sponsors

National Cancer Institute (NCI) (21)  ·  European Organisation for Research and Treatment of Cancer - EORTC (7)  ·  Memorial Sloan Kettering Cancer Center (6)  ·  Sarcoma Alliance for Research through Collaboration (5)  ·  University of Alabama at Birmingham (5)  ·  Beijing Tiantan Hospital (4)  ·  Novartis Pharmaceuticals (4)  ·  Children's Oncology Group (3)  ·  Duke University (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  City of Hope Medical Center (2)  ·  Indiana University (2)  ·  Maria Sklodowska-Curie National Research Institute of Oncology (2)  ·  Mayo Clinic (2)  ·  NYU Langone Health (2)

Countries

United States (91)  ·  China (14)  ·  Canada (13)  ·  France (8)  ·  Australia (6)  ·  Netherlands (6)  ·  Belgium (5)  ·  Germany (5)  ·  Puerto Rico (5)  ·  United Kingdom (5)  ·  Denmark (4)  ·  New Zealand (4)  ·  Switzerland (4)  ·  Poland (3)  ·  Spain (3)

Top investigators

Brigitte C Widemann, M.D. (4)  ·  AeRang Kim, MD, PhD (3)  ·  Henry S. Friedman, MD (3)  ·  Brigitte C. Widemann, MD (2)  ·  Brigitte Widemann, MD (2)  ·  Chie-Schin Shih, MD (2)  ·  Fu Zhao (2)  ·  Pinan Liu (2)  ·  William Tap, MD (2)  ·  Aaron R Weiss (1)  ·  Aaron Tward, MD (1)  ·  Albert S Cornelius, MD (1)  ·  Alexander Wei, MD (1)  ·  Andrew Cluster, M.D. (1)

Results publications

PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16408203, PMID 16528479, PMID 17095209, PMID 17336054, PMID 17610262, PMID 18989154, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20381270, PMID 20471824, PMID 23382028, PMID 24215845, PMID 24500418, PMID 24753394, PMID 26976425, PMID 27502708, PMID 27510726, PMID 28029918, PMID 30284154, PMID 30339775, PMID 30410720, PMID 31401903, PMID 31881853, PMID 31969335, PMID 32089640, PMID 32187457, PMID 32562630, PMID 32702309, PMID 32827353, PMID 33362722, PMID 33442015, PMID 33507822, PMID 33536190, PMID 33882143, PMID 34321280, PMID 34331515, PMID 34380663, PMID 34515544, PMID 34716198, PMID 35007270, PMID 35229827, PMID 35467749

NIH funding

U10CA098543 (6), P30CA008748 (3), U10CA180886 (3), N01CM62206 (2), P30CA033572 (2), U10CA180821 (2), 2009 (1), 2017 (1), 2018 (1), N01CM17104 (1), N01CM62201 (1), N01CM62205 (1), P30CA006973 (1), P30CA012197 (1), P30CA013148 (1)